Patent application number | Description | Published |
20090029910 | COMBINATIONS OF SOMATOSTATIN-ANALOGS WITH DIFFERENT SELECTIVITY FOR HUMAN SOMATOSTATIN RECEPTOR SUBTYPES - The present invention relates to a combination of two or more Somatostatin (SRIF) peptidomimetics (also referred to as Somatostatin- or SRIF-analogs) which have different selectivity for the five human somatostatin receptor subtypes, the use of such combination in the treatment of a disease mediated by activation of somatostatin receptors, and to pharmaceutical compositions comprising such a combination. | 01-29-2009 |
20090197815 | COMBINATION OF SOMATOSTATIN-ANALOGS WITH DOPAMINE- OR GROWTH HORMONE RECEPTOR ANTAGONIST - The present invention concerns a product containing SandostatinĀ® LARĀ® at 40 mg/28 days or pasireotide and either a dopamine-agonist, preferably cabergoline, or a growth hormone receptor antagonist, preferably pegvisomant, as a combined preparation for simultaneous, separate or sequential use in acromegalic therapy. In particular, this therapy is useful for treating acromegalic patients not achieving biochemical normalization after at least six-month treatment using at least one somatostatin analogue at conventional regimen. | 08-06-2009 |
20100069296 | USE OF SOMATOSTATIN ANALOGS IN CLUSTER HEADACHE - The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of cluster headache. | 03-18-2010 |
20110124555 | USE OF SOMATOSTATIN ANALOGS IN CONTROL OF HYPOGLYCEMIA - The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the control of hypoglycemia. | 05-26-2011 |
20110319329 | USE OF SOMATOSTATIN ANALOGS IN CLUSTER HEADACHE - The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of cluster headache. | 12-29-2011 |
20130123272 | ORGANIC COMPOUND FOR USE IN THE TREATMENT OF LIVER CANCER - The use of 4-amino-5-fluoro-3[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one or a pharmaceutically acceptable salt or a tautomer thereof, or a hydrate or a solvate for the manufacture of pharmaceutical compositions for use in the treatment of hepatocellular carcinoma or liver cancer. | 05-16-2013 |
20130237480 | COMBINATIONS OF SOMATOSTATIN-ANALOGS WITH DIFFERENT SELECTIVITY FOR HUMAN SOMATOSTATIN RECEPTOR SUBTYPES - The present invention relates to a combination of two or more Somatostatin (SRIF) peptidomimetics (also referred to as Somatostatin- or SRIF-analogs) which have different selectivity for the five human somatostatin receptor subtypes, the use of such combination in the treatment of a disease mediated by activation of somatostatin receptors, and to pharmaceutical compositions comprising such a combination. | 09-12-2013 |